Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRHR1 | P34998 | 17/20 | 0.47 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5600115 | 0.76 | CRHR1 (0.55) | CRHR1 | |
| SCHEMBL5872493 | 0.73 | CRHR1 (0.80) | CRHR1 | |
| SCHEMBL5872445 | 0.73 | CRHR1 (0.73) | CRHR1 | |
| SCHEMBL6049666 | 0.69 | GSK3A (0.47) | CRHR1KDM4EHPGD | |
| SCHEMBL5600192 | 0.65 | CRHR1 (0.84) | CRHR1 | |
| SCHEMBL16606731 | 0.63 | CRHR1 (1.00) | CRHR1 | |
| SCHEMBL7140515 | 0.63 | HTR6 (0.61) | HTR6 | |
| SCHEMBL6049455 | 0.63 | HSP90AA1 (0.53) | CRHR1KDM4EALDH1A1HPGD | |
| SCHEMBL7434787 | 0.62 | CRHR1 (0.57) | CRHR1 | |
| SCHEMBL5728817 | 0.62 | CRHR1 (0.82) | CRHR1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-11-30 | — | — | US | disclosed |
| EP-0880523-B1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES INC (US) | 2006-08-16 | — | — | EP | disclosed |
| US-7074797-B2 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2006-07-11 | — | — | US | disclosed |
| US-20040127483-A1 | Pyrazolopyrimidines as CRF receptor antagonists | NEUROCRINE BIOSCIENCES, INC. (US) | 2004-07-01 | — | — | US | disclosed |
| US-6664261-B2 | Endocrine, psychiatric and neurologic disorders from hypersecretion of corticotropin-releasing factor | NEUROCRINE BIOSCIENCES, INC. | 2003-12-16 | — | — | US | disclosed |
| US-20030125341-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | NEUROCRINE BIOSCIENCES, INC. | 2003-07-03 | — | — | US | disclosed |
| EP-0880523-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1998-12-02 | — | — | EP | disclosed |
| WO-1997029109-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | JANSSEN PHARMACEUTICA N.V. (BE) | 1997-08-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127483-A1 | Pyrazolopyrimidines as CRF receptor antagonists | CRHR1, CRHR2, CRH | CRHR1 1/4885HTR6 5/4885KDM4E 2814/4885 |
| US-20060270659-A1 | Pyrazolopyrimidines as CRF receptor antagonists | HTR5A, OPRL1, CRHR1 | CRHR1 3/4885HTR6 39/4885KDM4E 3366/4885 |
| US-20030125341-A1 | PYRAZOLOPYRIMIDINES AS CRF RECEPTOR ANTAGONISTS | CRHR1, CRHR2, OPRL1 | CRHR1 1/4885HTR6 8/4885KDM4E 3509/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.